info@seagull-health.com
SeagullHealth
语言:
search
new
What Are the Indications of Mitiglinide Calcium Tablets (Glufast)?
502
Article source: Seagull Pharmacy
Nov 19, 2025

Mitiglinide Calcium Tablets (Glufast) are an oral hypoglycemic drug used for the treatment of type 2 diabetes, belonging to the class of fast-acting insulin secretagogues. Its mechanism of action is to promote insulin secretion from pancreatic β-cells, thereby rapidly controlling blood glucose levels after meals.

What Are the Indications of Mitiglinide Calcium Tablets (Glufast)?

Main Indications

Mitiglinide Calcium Tablets are indicated for the treatment of type 2 diabetes.

This drug is mainly used in patients whose blood glucose remains poorly controlled despite diet management and exercise therapy.

It is characterized by rapid onset and short duration of action, making it particularly suitable for controlling postprandial blood glucose elevation.

Precautions

Patients should use this drug under the guidance of a doctor and strictly follow the prescribed dosage.

This drug is suitable for patients with a fasting blood glucose level ≥ 126 mg/dL, or a 1-hour or 2-hour postprandial blood glucose level ≥ 200 mg/dL.

Blood glucose should be monitored regularly during treatment. If the therapeutic effect is unsatisfactory after 2 to 3 consecutive months of use, consideration should be given to adjusting the treatment plan.

Specifications and Properties of Mitiglinide Calcium Tablets (Glufast)

Regular Tablets (5 mg and 10 mg)

5 mg tablets: White uncoated tablets, approximately 6.0 mm in diameter, 2.0 mm in thickness, and about 75 mg in weight.

10 mg tablets: White uncoated tablets with a score line, approximately 10.0 mm in major diameter, 5.0 mm in minor diameter, 3.0 mm in thickness, and about 150 mg in weight.

The active ingredient is mitiglinide calcium hydrate. Excipients include corn starch, hydroxypropyl cellulose, calcium stearate, microcrystalline cellulose, lactose hydrate, etc.

Orally Disintegrating Tablets (OD Tablets, 5 mg and 10 mg)

5 mg OD tablets: Pale yellowish-white uncoated tablets, approximately 6.4 mm in diameter, 3.1 mm in thickness, and about 100 mg in weight.

10 mg OD tablets: Pale yellowish-white uncoated tablets with a score line, approximately 8.0 mm in diameter, 3.8 mm in thickness, and about 200 mg in weight.

The active ingredient is also mitiglinide calcium hydrate. Excipients include D-mannitol, crospovidone, stevioside, flavoring agents, etc., which enable the tablets to disintegrate rapidly in the mouth.

Usage Characteristics

Regular tablets should be swallowed with water.

OD tablets can disintegrate rapidly in the mouth with saliva, no water is needed for swallowing, and they can also be taken with water. They are suitable for patients with swallowing difficulties. However, it should be noted that OD tablets should not be taken without water when lying in bed.

Storage Methods for Mitiglinide Calcium Tablets (Glufast)

Storage Environment

All specifications of tablets should be stored at room temperature, away from high temperatures, moisture, and direct sunlight.

Expiration Period

The expiration period of regular tablets (5 mg and 10 mg) is 3 years.

The expiration period of orally disintegrating tablets (OD tablets) is 5 years.

Precautions

The drug should be stored out of the reach of children.

Drugs in PTP (Press-Through Package) blister packs must be taken out of the aluminum foil before use to avoid accidental ingestion of the package, which may cause esophageal injury.

After opening the package of OD tablets, moisture should be avoided. It is recommended to store them in a sealed container to prevent the tablet surface from absorbing moisture and affecting quality.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Purchase Channels for Mitiglinide Calcium Tablets (Glufast)?
Mitiglinide Calcium Tablets (Glufast) are a fast-acting insulin secretagogue used for the treatment of type 2 diabetes, primarily indicated for postprandial blood glucose control. As a prescription dr...
Side Effects of Tivozanib (Fotivda)
Tivozanib (Fotivda) is a kinase inhibitor clinically used for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC) after two or more lines of systemic therapy. It provides an im...
How to Use Dificid (Fidaxomicin)
Dificid (fidaxomicin) is a macrolide antibacterial agent, primarily used to treat Clostridioides difficile - associated diarrhea (CDAD) in adult patients and pediatric patients aged 6 months and older...
What Kind of Drug Is Dificid (Fidaxomicin)?
Dificid (fidaxomicin) is a new-generation macrolide antibacterial agent. It plays an important role in the treatment of Clostridioides difficile infections through a unique targeted mechanism of actio...
Dosage and Administration of Mitiglinide Calcium Tablets (Glufast)
Mitiglinide Calcium Tablets (Glufast) is a rapid-acting insulin secretagogue, mainly used for the treatment of type 2 diabetes. Its mechanism of action is to promote the secretion of insulin by pancre...
Side Effects of Mitiglinide Calcium Tablets (Glufast)
Mitiglinide Calcium Tablets (Glufast) is a rapid-acting insulin secretagogue, primarily indicated for the treatment of type 2 diabetes. It works by stimulating pancreatic β-cells to promote insulin se...
What Are the Precautions for Taking Mitiglinide Calcium Tablets (Glufast)?
Mitiglinide Calcium Tablets (Glufast) is a rapid-acting insulin secretagogue, mainly used for the treatment of type 2 diabetes. Its mechanism of action is to promote the secretion of insulin by pancre...
How to Purchase Tucatinib (Tukysa)
Tucatinib (Tukysa) is a new-generation HER2-targeted therapeutic agent that has demonstrated significant efficacy in the treatment of HER2-positive metastatic breast cancer and colorectal cancer. As a...
Related Articles
Dosage and Administration, Recommended Dose of Elacestrant (Orserdu)
Elacestrant (Orserdu) is a selective estrogen receptor degrader (SERD), which provides an important treatment option for patients with estrogen receptor-positive, HER2-negative advanced or metastatic ...
What Are the Indications for Elacestrant (Orserdu)?
Elacestrant (Orserdu) is a novel endocrine therapy agent that demonstrates significant value in the treatment of advanced breast cancer with specific gene mutations. As an estrogen receptor antagonist...
What Are the Purchase Channels for Elacestrant (Orserdu)?
With the advancement of medical technology, elacestrant (Orserdu), a targeted drug for breast cancer with specific gene mutations, has brought new treatment options for patients. As the first oral sel...
Adverse Reactions of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer harboring MET gene mutations. By precisely inhibiting the act...
What are the Precautions for Capmatinib (Tabrecta) Administration?
Capmatinib (Tabrecta) is a targeted therapy drug for MET gene mutations, demonstrating significant efficacy in the treatment of advanced malignancies such as non-small cell lung cancer.What are the Pr...
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved